TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04998396: A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Sponsor: Aspa Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 26 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$761,940

Rescue Site Savings

+$507,960

Unlock Full NCT04998396 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04998396 Rescue Dossier →